GlassScriptPhysician profile
Thomas A Planchard
NPI 1104818905
$3,178.07
in general payments reported to CMS, 2019-2025
24 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $195 · 2021: $340 · 2022: $533 · 2023: $430 · 2024: $304 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $510.06 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $313.03 | 2019-2025 | Clareon, Unity, Rocklatan |
| Novartis Pharmaceuticals Corporation | $281.17 | 2019-2023 | |
| Glaukos Corporation | $266.91 | 2025 | Idosetr |
| Allergan, INC. | $254.39 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $246.68 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $214.16 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Omeros Corporation | $176.84 | 2019-2020 | |
| Abbvie INC. | $132.53 | 2022-2024 | |
| Amgen INC. | $123.14 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec, INC. | $100.82 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $99.34 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $88.50 | 2022-2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $68.85 | 2019-2021 | |
| Horizon Therapeutics Plc | $66.38 | 2022-2023 | Tepezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $62.99 | 2020-2021 | |
| Harrow Eye, LLC | $43.13 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $31.96 | 2022-2025 | |
| Shire North American Group INC | $20.44 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.51 | 2021 | |
| Dompe US, INC. | $16.66 | 2021 | |
| Rxsight INC | $14.49 | 2022 | |
| Sight Sciences, INC. | $14.29 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Genentech USA, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Planchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.